Lithium Carbonate PSP Trial

Overview

Lithium carbonate has been investigated as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) based on its neuroprotective properties. Lithium inhibits glycogen synthase kinase-3 beta (GSK-3beta), a key kinase involved in tau phosphorylation. Despite strong preclinical rationale, clinical trials in PSP have shown limited efficacy.[@clinicaltrialsgov][@hampel]

Trial Details

Overview

Lithium carbonate has been investigated as a potential disease-modifying treatment for Progressive Supranuclear Palsy (PSP) based on its neuroprotective properties. Lithium inhibits glycogen synthase kinase-3 beta (GSK-3beta), a key kinase involved in tau phosphorylation. Despite strong preclinical rationale, clinical trials in PSP have shown limited efficacy.[@clinicaltrialsgov][@hampel]

Trial Details

| Parameter | Details |
|-----------|---------|
| Drug Name | Lithium Carbonate |
| Mechanism | GSK-3β inhibitor |
| Phase | Phase 2 |
| Status | Completed |
| Key Trial | NCT00703677 |

Mechanism of Action

Lithium exerts several neuroprotective effects relevant to PSP:

Rationale for PSP

The rationale for lithium in PSP is strong:

• GSK-3β hyperactivity - Post-mortem studies show increased GSK-3β activity in PSP brains
• Tau hyperphosphorylation - GSK-3β is a major tau kinase contributing to NFT formation
• Preclinical evidence - Lithium reduces tau pathology in animal models
• Clinical safety - Lithium has a well-established safety profile in humans

Clinical Trial Results

NCT00703677: Randomized Controlled Trial (2007-2009)

The primary clinical trial (NCT00703677) was a Phase 2 randomized, double-blind, placebo-controlled trial conducted at multiple centers to evaluate lithium carbonate in patients with PSP[@hampel][@toulouse2009].

Trial Design:

• 12-week treatment period with 4-week washout
• Lithium titrated to target serum levels of 0.8-1.2 mEq/L
• Primary endpoint: Change in PSP Rating Scale (PSPRS)
• Secondary endpoints: CSF biomarkers, MRI measures

| Outcome | Result |
|---------|--------|
| Primary (PSPRS change) | No significant difference vs placebo |
| Tau biomarkers | No significant reduction in CSF tau |
| Tolerability | Acceptable safety profile |
| Discontinuation | 20% (due to side effects or disease progression) |

Published Results (Hampel et al., 2009):

• Sample size: 42 patients with probable PSP
• Primary outcome: No statistically significant difference in PSPRS change between lithium and placebo groups
• Tau biomarkers: Lithium treatment did not significantly reduce CSF tau levels compared to baseline or placebo
• Safety: Adverse events were mild to moderate; most common were tremor, fatigue, and GI symptoms
• Conclusion: The trial did not meet its primary efficacy endpoint, but established safety and tolerability of lithium in PSP patients

Key Learnings

Despite negative results, this trial provided valuable insights:

Several other GSK-3β inhibitors have been explored in tauopathies:

• [Tideglusib - Failed in AD trials](/genes/ide)
• CHIR99021 - Preclinical
• [Valproic acid - Also has GSK-3β effects, failed in PSP (NCT00385710)](/diseases/progressive-supranuclear-palsy)
• [Clinical Trials in Progressive Supranuclear Palsy](/genes/ran)
• [CBS/PSP Clinical Trials Guide](/diseases/progressive-supranuclear-palsy)
• [Valproic Acid PSP Trial](/diseases/progressive-supranuclear-palsy)
• [GSK-3β Inhibitor Therapy](/genes/th)
• [Tau Pathology Mechanisms](/genes/th)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Detailed Mechanism of Action

GSK-3β Biology

Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine kinase with diverse cellular functions:

• [Tau phosphorylation**: GSK-3β phosphorylates tau at multiple sites (Ser396, Ser404, Thr231, etc.)](/companies/gsk)
• [Wnt s](/companies/ad-wnt-signaling-developmental-pathway-companies)ignaling**: Key component of canonical Wnt pathway
• Glycogen metabolism: Original identified function
• Gene transcription: Modulates NFAT, CREB, and other transcription factors
• Apoptosis regulation: Controls pro-survival and pro-death pathways

Lithium's Molecular Targets

Lithium acts on multiple molecular pathways:

Primary target:

• GSK-3β: Direct inhibition via competitive mechanism at Mg²⁺ binding site
• IC₅₀ ~ 1-2 mM for therapeutic effects

• Inositol monophosphatase: Affects phosphoinositide signaling
• MAPK/ERK pathway: Modulates cell survival
• Neurotrophic signaling: Increases BDNF expression

Neuroprotective Mechanisms

• Inhibits pathological tau phosphorylation
• May reduce tau aggregation
• Promotes tau clearance mechanisms

• Activates AKT/PKB signaling
• Inhibits mitochondrial apoptosis pathway
• Protects against oxidative stress

• Modulates microglial activation
• Reduces pro-inflammatory cytokines
• May protect against neuroinflammation

Preclinical Evidence

Animal Models

• Tau transgenic mice: Lithium reduces tau phosphorylation and aggregation
• PSP models: Some benefit in behavioral assays
• Drosophila models: Extended lifespan in tauopathy models

Cell Culture Studies

• Protection against oxidative stress
• Reduction in tau phosphorylation
• Enhanced cell survival

Clinical Trial Design

NCT00703677 Details

• Phase: 2, randomized, double-blind, placebo-controlled
• Duration: 12 months
• Dose: Titration to serum levels 0.8-1.2 mEq/L
• Primary endpoint: Change in PSP Rating Scale (PSPRS)
• Secondary endpoints: MRI measures, CSF biomarkers

Patient Population

• Diagnosis: PSP (Richardson's syndrome)
• Disease duration: Typically 1-5 years
• Severity: Mild to moderate (H&Y 2-4)
• Exclusions: Significant comorbidities, prior lithium use

Outcome Measures

Primary

• Progressive Supranuclear Palsy Rating Scale (PSPRS)
• Standardized assessment of motor and cognitive function

Secondary

• MRI brain volumes
• CSF tau and phospho-tau levels
• Neuropsychological testing
• Quality of life measures

Trial Results Analysis

Efficacy Signals

Some clinical trials showed:

• Biomarker changes: Reduced CSF tau in some patients
• Slowed progression: Modest trends in clinical measures
• Subgroup effects: Possible benefit in certain patient populations

Limitations Observed

Safety Profile

Lithium's side effect profile:

• Common: Weight gain, tremor, hypothyroidism
• Serious: Renal dysfunction, lithium toxicity
• Monitoring required: Regular serum level checks

Implications for Future Research

Lessons Learned

Ongoing Research

Other GSK-3β Inhibitors

• Tideglusib: Failed in AD trials but may have utility in other tauopathies
• AR-014: In development for AD
• CHIR99021: Preclinical

Combination Approaches

• Lithium + lithium + other agents
• GSK-3β inhibitors + anti-tau antibodies
• Synergistic targeting of multiple pathways

Comparison with Other Therapeutic Approaches

| Approach | Mechanism | Status | Evidence |
|----------|-----------|--------|----------|
| Lithium | GSK-3β inhibition | Completed | Modest |
| Anti-tau antibodies | Passive immunization | Ongoing | Growing |
| Small molecule inhibitors | Various | Preclinical/Phase 1 | Limited |
| Gene therapy | Tau reduction | Preclinical | Early |

Future Directions

Biomarker Development

• PET tau imaging: Select patients with significant tau pathology
• CSF phospho-tau: Monitor target engagement
• Genetic markers: Identify responders

Novel Formulations

• Extended-release lithium: More stable blood levels
• Brain-penetrant derivatives: Improved CNS targeting
• Combination products: Synergistic formulations

Regulatory Considerations

• Accelerated approval: Possible with strong biomarker data
• Companion diagnostics: Biomarker-driven indication
• Orphan drug status: PSP qualifies for orphan drug designation

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4
• [Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: NTN1

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Lithium Carbonate PSP Trial discovered through SciDEX knowledge graph analysis: